Profile data is unavailable for this security.
About the company
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The Company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI). Flynpovi is a combination of CPP-1X (eflornithine) and sulindac. It has a dual mechanism of action whereby it suppresses the synthesis of new polyamines and increases the export and catabolism of polyamines from the diet and microbiome. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes metastatic castration-resistant prostate cancer, and STK-11 mutant NSCLC.
- Revenue in USD (TTM)0.00
- Net income in USD-28.56m
- Incorporated2011
- Employees7.00
- LocationPanbela Therapeutics Inc712 Vista Blvd # 305WACONIA 55387United StatesUSA
- Phone+1 (952) 479-1196
- Websitehttps://panbela.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
LadRx Corp | 0.00 | -2.77m | 1.23m | 2.00 | -- | -- | -- | -- | -5.59 | -5.59 | 0.00 | -1.89 | 0.00 | -- | -- | 0.00 | -113.62 | -58.97 | -653.73 | -78.44 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 106.96 | -- | -- | -- |
GRI Bio Inc | 0.00 | -8.28m | 1.29m | 4.00 | -- | 0.0749 | -- | -- | -100.69 | -100.69 | 0.00 | 5.88 | 0.00 | -- | -- | 0.00 | -130.64 | -192.93 | -187.01 | -353.99 | -- | -- | -- | -37,650.49 | -- | -- | 0.00 | -- | -- | -- | -85.61 | -- | 29.46 | -- |
Emmaus Life Sciences Inc | 19.97m | -5.26m | 1.34m | 51.00 | -- | -- | -- | 0.0672 | -0.0824 | -0.0824 | 0.2506 | -0.8927 | 0.5239 | 0.5247 | 3.93 | 391,529.40 | -13.79 | -- | -- | -- | 95.48 | -- | -26.32 | -- | 0.1153 | -0.1451 | -- | -- | 60.94 | -- | 64.87 | -- | -- | -- |
Regen BioPharma Inc | 236.57k | -882.60k | 1.35m | 1.00 | -- | -- | -- | 5.72 | -0.2157 | -0.2157 | 0.0594 | -1.18 | 1.04 | -- | 3.82 | 236,570.00 | -407.33 | -104.36 | -- | -- | -- | -- | -392.01 | -275.00 | -- | -1.36 | -- | -- | 0.4416 | 18.79 | -58.11 | -- | -- | -- |
Aditxt Inc | 329.75k | -43.31m | 1.38m | 47.00 | -- | 0.1162 | -- | 4.18 | -77.20 | -77.20 | 0.303 | 3.29 | 0.0185 | 0.6082 | 0.8393 | 7,015.96 | -242.33 | -192.78 | -1,548.63 | -321.59 | -46.09 | -- | -13,105.77 | -7,208.65 | 0.0458 | -3.53 | 0.5084 | -- | -30.90 | -- | -18.11 | -- | -- | -- |
Seelos Therapeutics Inc | 2.01m | 4.09m | 1.40m | 8.00 | 0.0205 | -- | -- | 0.6941 | 9.76 | 9.76 | 1.43 | -8.47 | 0.2823 | -- | 6.51 | 134,266.70 | 57.34 | -180.05 | -- | -386.76 | -- | -- | 203.13 | -9,612.88 | -- | -608.33 | -- | -- | -- | -- | 48.48 | -- | -- | -- |
Aclarion Inc | 53.95k | -5.90m | 1.60m | 6.00 | -- | 0.885 | -- | 29.64 | -4.74 | -4.74 | 0.0146 | 0.20 | 0.0212 | -- | 3.59 | 8,991.67 | -231.70 | -- | -714.18 | -- | -51.53 | -- | -10,937.05 | -- | -- | -111.15 | 0.3212 | -- | 24.75 | -- | 34.38 | -- | -- | -- |
Panbela Therapeutics Inc | 0.00 | -28.56m | 1.65m | 7.00 | -- | -- | -- | -- | -84.64 | -84.64 | 0.00 | -2.18 | 0.00 | -- | -- | 0.00 | -197.23 | -215.89 | -3,522.07 | -476.38 | -- | -- | -- | -- | -- | -143.57 | -- | -- | -- | -- | 27.68 | -- | -- | -- |
Hi-Great Group Holding Co | 71.99k | -74.35k | 1.78m | -- | -- | -- | -- | 24.73 | -0.0007 | -0.0007 | 0.0007 | -0.0013 | 0.7149 | 0.627 | -- | -- | -73.83 | -- | -- | -- | 51.28 | -- | -103.28 | -- | 0.0099 | -20.74 | -- | -- | -47.32 | -- | -3,789.70 | -- | -- | -- |
Axim Biotechnologies Inc | 92.90k | -4.14m | 1.81m | 6.00 | -- | -- | -- | 19.50 | -0.0163 | -0.0163 | 0.0003 | -0.0324 | 0.0233 | -- | -- | 15,483.33 | -103.73 | -154.34 | -- | -390.73 | 16.94 | -- | -4,451.97 | -36,362.71 | -- | -3.14 | -- | -- | 345.05 | -27.38 | -29.10 | -- | -- | -- |
Pharmagreen Biotech Inc | 1.56k | -500.66k | 1.92m | 0.00 | -- | -- | -- | 1,233.70 | -0.0011 | -0.0011 | 0.00 | -0.0045 | 0.0094 | -- | 3.35 | -- | -302.10 | -472.20 | -- | -- | 11.54 | -- | -32,096.15 | -- | 0.0194 | -71.71 | -- | -- | -- | -- | 80.68 | -- | -- | -- |
Cyclacel Pharmaceuticals Inc | 80.00k | -17.61m | 1.93m | 12.00 | -- | 1.77 | -- | 24.18 | -16.14 | -16.14 | 0.0423 | 0.5534 | 0.0065 | -- | 0.0547 | -- | -142.14 | -57.58 | -327.21 | -69.81 | -- | -- | -21,882.50 | -18,789.29 | -- | -100.52 | 0.00 | -- | -- | 22.87 | -6.34 | -- | -31.23 | -- |
Novelstem International Corp | 18.00k | -1.65m | 1.97m | 15.00 | -- | -- | -- | 109.39 | -0.0352 | -0.0352 | 0.0004 | -0.0541 | 0.0081 | -- | 8.00 | -- | -63.77 | -- | -- | -- | -- | -- | -7,867.33 | -- | -- | -2.13 | 2.61 | -- | 0.00 | -- | -446.84 | -- | -- | -- |
180 Life Sciences Corp | 0.00 | -12.55m | 2.02m | 4.00 | -- | -- | -- | -- | -28.16 | -28.16 | 0.00 | -0.4439 | 0.00 | -- | -- | 0.00 | -142.80 | -42.39 | -270.23 | -56.41 | -- | -- | -- | -- | -- | -- | 18.20 | -- | -- | -- | 48.52 | -- | -- | -- |